


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. None of the Bonds will be offered to the public in Hong Kong or elsewhere, except to the professional investors as defined in the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or the securities laws of any state of the United States or other jurisdiction. The securities are being offered and sold outside the United States in reliance on Regulation S under the Securities Act and may not be offered or sold within the United States absent registration or an exemption from registration under the Securities Act. No public offering of the securities will be made in the United States or in any other jurisdiction.



The United Laboratories International Holdings Limited

聯邦制藥國際控股有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 3933)

ENGAGEMENT OF PLACING AGENT FOR THE ISSUE OF THE BONDS AND ANNOUNCEMENT PURSUANT TO RULE 13.18 OF THE LISTING RULES

ENGAGEMENT OF PLACING AGENT FOR THE ISSUE OF THE BONDS

The United Laboratories International Holdings Limited (the "**Company**"), and together with its subsidiaries, the "**Group**") refers to its announcement dated 12 January 2015, which relates to the establishment of a bond issue programme (the "**Programme**") for the issuance, from time to time, of bonds with a term of three years in an aggregate principal amount of up to HK\$1,000,000,000 (the "**Bonds**").

From the date of the establishment of the Programme up to the date of this announcement, the Company had issued Bonds in an aggregate principal amount of HK\$166,800,000. The Company plans to issue additional Bonds under the Programme. As the term of the previous placing agreement for the issuance and placement of the Bonds had expired, the Company on 2 February 2016 entered into a new placing agreement (the "**Placing Agreement**") with Vision Finance (Securities) Limited (the "**Placing Agent**") for the issuance and placement of the Bonds under the Programme. The Bonds may be placed by the Placing Agent in tranches subject to the then market conditions during a period of one year after the date of the Placing Agreement.

The Company proposes to use the net proceeds of the Bonds for the general working capital of the Group. None of the Bonds will be offered to the public in Hong Kong nor will they be issued to any connected persons (as defined in The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”)) of the Company. No application will be made to The Stock Exchange of Hong Kong Limited or any other stock exchanges for the listing of the Bonds.

Completion of the Placing Agreement is subject to the satisfaction of the conditions precedent set out therein, and is subject to termination in certain circumstances.

As the Placing Agreement may or may not complete and the Bonds may or may not be issued, shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

CHANGE OF CONTROL PUT OPTION

This announcement is made pursuant to Rule 13.18 of the Listing Rules.

Pursuant to the terms and conditions of the Bonds, at any time following the occurrence of a “change of control”, the holder of any Bond will have the right, at such holder’s option, to require the Company to redeem all but not some only of that holder’s Bonds at 101% of their principal amount, together with accrued interests up to the settlement date of the redemption of the Bonds. Pursuant to the terms and conditions of the Bonds, a “change of control” occurs, amongst other situations, if the controlling shareholder(s) of the Company (which include Mr. Tsoi Hoi Shan, the Chairman of the board of directors of the Company (the “**Board**”), his close relatives and any trust of which any of the aforementioned persons is a beneficiary or discretionary object) ceases to directly or indirectly own or control more than 35% of the voting rights of the issued share capital of the Company.

As at the date of this announcement, (i) Nautilus Trustees Asia Limited (formally known as DBS Trustee H.K. (Jersey) Limited) (as the trustee of The Choy Family Trust), through its wholly-owned subsidiaries, Gesell Holdings Limited and Heren Far East Limited and; (ii) Ms. Ning Kwai Chun, Mr. Tsoi Hoi Shan and Ms. Choy Siu Chit (all being members of the Choy family), are collectively holding 1,074,825,000 shares of the Company, representing approximately 66.07% of the issued share capital of the Company.

The Company will continue to comply with the disclosure obligations under Rule 13.21 of the Listing Rules for so long as circumstance giving rise to the above obligation continue to exist.

By order of the Board
The United Laboratories International Holdings Limited
Tsoi Hoi Shan
Chairman

Hong Kong, 3 February 2016

As at the date of this announcement, the Board comprises Mr. Tsoi Hoi Shan, Mr. Leung Wing Hon, Ms. Choy Siu Chit, Mr. Fang Yu Ping, Ms. Zou Xian Hong and Ms. Zhu Su Yan as executive directors; and Mr. Chong Peng Oon, Mr. Huang Bao Guang, Mr. Song Ming and Ms. Fu Xiao Nan as independent non-executive directors.